Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:923-924 (22 April), doi:10.1136/bmj.332.7547.923
One size does not fit all
| The first 150 words of the full text of this article appear below. |
Eczema (previously known as atopic dermatitis or atopic eczema)1 affects up to 20% of children worldwide.2 Although most eczema in children is mild,3 caring for a child with chronic severe eczema can be distressing. Sleep disturbance from scratching affects the whole family,4 and witnessing a child scratching their limbs until they bleed is agonising. In this week's BMJ a randomised controlled trial by Staab and colleagues (p 933) reports an evaluation of educational programmes for young people with eczema and their families, and provides new and useful evidence.5
Eczema carries a high economic burden, with costs comparable to asthma.6 The causes of eczema are unclear, and treatment is geared largely around restoring the barrier function of the dry skin typical of eczema, and by suppressing skin inflammation with topical corticosteroids and other topical or systemic agents.7
A systematic review of 272 randomised controlled trials of eczema treatments
Hywel C Williams, professor of dermato-epidemiology
Centre for Evidence-Based Dermatology, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH
(hywel.williams@nottingham.ac.uk)
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+